Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab, Bevacizumab, and Chemotherapy in EGFR+ High PD-L1 NSCLC
NCT05394233Phase 2Unknown
- Sponsor
- Sichuan Cancer Hospital
- Start
- Jun 2022
- Primary completion
- Dec 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of tislelizumab in non-small cell lung cancer (NSCLC), sponsored by Sichuan Cancer Hospital. Status: unknown.
02
Drugs
tislelizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05394233.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05394233.